You are here

RGX-181, a Candidate for Life-Threatening Form of Batten Disease

Possible One-Time Treatment for Rare Pediatric CLN2 Disease

The FDA has granted REGENXBIO Inc. a rare pediatric disease designation for RGX-181, for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease. 

CLN2 is a rare, autosomal recessive, neurodegenerative lysosomal storage disorder caused by mutations in the TPP1 gene. The disease is characterized by seizures, rapid language and motor function deterioration, cognitive decline, loss of vision and blindness, and premature death by mid-childhood. Symptom onset is usually between the ages of two to four years. There is currently no cure for CLN2 disease. 

RGX-181 is being developed as a novel, one-time treatment for CLN2 disease using REGENXBIO’s NAV AAV9 vector to deliver the TPP1 gene directly into the central nervous system (CNS). TPP1 is an enzyme that is deficient in children who have CLN2 disease. RGX-181 treatment is designed to modify cells in the CNS and provide a lasting source of TPP1.

Source: RegenXBio, January 31, 2019

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs